Published in World J Surg Oncol on April 29, 2008
An unusual case of locally advanced glycogen-rich clear cell carcinoma of the breast. Case Rep Oncol (2011) 0.89
Clear Cell Carcinoma of the Breast: A Rare Breast Cancer Subtype - Case Report and Literature Review. Case Rep Oncol (2015) 0.84
Intraductal glycogen-rich clear cell carcinoma of the breast: a rare presentation and review of the literature. Breast Care (Basel) (2012) 0.81
Invasive ductal carcinoma of the breast with osteoclast-like giant cells and clear cell features: a case report of a novel finding and review of the literature. World J Surg Oncol (2016) 0.75
Solitary metastatic clear cell carcinoma to the spleen. Rare Tumors (2011) 0.75
Glycogen-rich clear cell carcinoma of the breast: a case report. J Med Ultrason (2001) (2009) 0.75
Benign clear cell ("sugar") tumors of the lung. Yale J Biol Med (1971) 1.32
Glycogen-rich clear cell carcinoma of the breast. A clinicopathologic study of 21 cases. Am J Surg Pathol (1995) 1.26
CLEAR-CELL CARCINOMA OF THE LUNG. J Pathol Bacteriol (1964) 1.25
Glycogen-rich clear-cell carcinoma of the breast: a clinicopathologic and flow cytometric study. Hum Pathol (1991) 1.16
Glycogen-rich clear cell carcinoma of the breast: a light and electron microscopic study. Cancer (1981) 1.16
Signet-ring cell carcinoma of the breast: a clinicopathologic study of 24 cases. Am J Clin Pathol (1980) 1.08
Metastatic mammary carcinoma in the eyelid with histiocytoid appearance. Cancer (1973) 1.00
Papillary clear cell carcinoma of the thyroid gland. Hum Pathol (1975) 0.92
Secretory (juvenile) carcinoma of the breast. Pathology (1977) 0.88
Clear cell carcinoma of the larynx A variant of mucoepidermoid carcinoma. Ann Otol Rhinol Laryngol (1980) 0.86
Benign clear cell tumor of lung with necrosis. Cancer (1976) 0.84
Electron microscopy of clear cell thyroid carcinoma. Arch Pathol Lab Med (1977) 0.83
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol (2009) 2.63
Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Breast Cancer Res Treat (2008) 1.82
Melanocortin receptor-1 gene polymorphisms and the risk of cutaneous melanoma in a low-risk southern European population. J Invest Dermatol (2006) 1.80
Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival. Breast Cancer Res Treat (2006) 1.43
Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group. Clin Breast Cancer (2003) 1.32
Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Breast Cancer Res (2010) 1.30
The effects of age on DNA fragmentation, chromatin packaging and conventional semen parameters in spermatozoa of oligoasthenoteratozoospermic patients. J Assist Reprod Genet (2007) 1.24
Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel. PLoS One (2012) 1.12
New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res (2011) 1.12
IFN-α in the treatment of melanoma. J Immunol (2012) 1.12
Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer (2008) 1.03
Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast Cancer Res Treat (2012) 1.01
Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Breast Cancer Res Treat (2006) 0.97
Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women. Breast Cancer Res Treat (2005) 0.95
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med (2013) 0.95
Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study. Breast Cancer Res Treat (2011) 0.94
Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients. Breast Cancer Res Treat (2007) 0.94
Replication and predictive value of SNPs associated with melanoma and pigmentation traits in a Southern European case-control study. PLoS One (2013) 0.92
Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression. Clin Breast Cancer (2012) 0.91
Prognostic significance of autoimmunity during treatment of melanoma with interferon. Semin Immunopathol (2011) 0.90
Risk associations of melanoma in a Southern European population: results of a case/control study. Cancer Causes Control (2008) 0.90
The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial. Breast Cancer Res (2012) 0.89
HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. J Transl Med (2012) 0.89
Nonmelanoma skin tumors involving the craniofacial region: our 22 years of experience. J Craniofac Surg (2007) 0.89
Metastatic melanoma in the gallbladder: report of a case. Surg Today (2003) 0.88
Survival from breast cancer in relation to access to tertiary healthcare, body mass index, tumor characteristics and treatment: a Hellenic Cooperative Oncology Group (HeCOG) study. Eur J Epidemiol (2012) 0.87
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med (2012) 0.87
Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer. Support Care Cancer (2014) 0.85
Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy. Breast Cancer Res (2009) 0.85
Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. Breast Cancer Res Treat (2005) 0.85
Molecular markers detecting circulating melanoma cells by reverse transcription polymerase chain reaction: methodological pitfalls and clinical relevance. Clin Chem Lab Med (2009) 0.85
Severe thrombocytopenia related to trastuzumab infusion. Med Sci Monit (2011) 0.84
Myelotoxicity as a prognostic factor in patients with advanced breast cancer treated with chemotherapy: a pooled analysis of two randomised trials conducted by the Hellenic Cooperative Oncology Group. Anticancer Res (2008) 0.84
Insulin resistance in relation to melanoma risk. Melanoma Res (2011) 0.83
Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study. Anticancer Res (2005) 0.83
A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon. PLoS One (2012) 0.82
The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. Melanoma Res (2004) 0.82
Methods of detection of circulating melanoma cells: a comparative overview. Cancer Treat Rev (2010) 0.82
A study of a single variant allele (rs1426654) of the pigmentation-related gene SLC24A5 in Greek subjects. Exp Dermatol (2008) 0.81
Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Oncology (2008) 0.81
Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). Cancer Invest (2004) 0.81
Diagnosis and treatment of intracystic breast carcinomas. Am Surg (2002) 0.81
Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel. Anticancer Res (2007) 0.80
Treatment algorithms in stage IV melanoma. Am J Ther (2015) 0.80
Salvage chemotherapy with oxaliplatin and capecitabine for breast cancer patients pretreated with anthracyclines and taxanes. Anticancer Res (2009) 0.79
Evaluation of self-assessed melanoma growth rate in a Mediterranean patient population. Melanoma Res (2011) 0.78
Advances in adjuvant therapy: potential for prognostic and predictive biomarkers. Methods Mol Biol (2014) 0.78
A rare retroperitoneal tumor. Saudi J Gastroenterol (2011) 0.78
Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer. Anticancer Res (2003) 0.78
Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. J Cancer Res Clin Oncol (2012) 0.77
Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer. Med Oncol (2006) 0.77
Subsets of patients with advanced gastric cancer responding to second-line chemotherapy with docetaxel-cisplatin. Anticancer Res (2006) 0.77
Surgical education in Greece. World J Surg (2008) 0.77
Expression of p27KIP1, p21WAF1 and p53 does not correlate with prognosis in node-negative invasive ductal carcinoma of the breast. Anticancer Res (2006) 0.76
Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group. Lung Cancer (2003) 0.76
Cisplatin-Ifosfamide-gemcitabine as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and Paclitaxel. Anticancer Res (2009) 0.76
Intensive weekly chemotherapy with docetaxel, epirubicin and carboplatin with G-CSF support in patients with advanced gastric cancer: a Hellenic Cooperative Oncology Group (HeCOG) phase II study. Med Oncol (2007) 0.76
The effects of age on the incidence of aneuploidy rates in spermatozoa of oligoasthenozoospermic patients and its relationship with ICSI outcome. Int J Androl (2006) 0.76
Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: feasibility and reproducibility in a multi-institutional Hellenic collaborative study. Oncol Rep (2010) 0.75
Mucosa-associated lymphoid tissue thyroid lymphoma: a rare and not aggressive tumour. Eur J Surg (2002) 0.75
The role of adiponectin as a compensatory mediator for the primary secretory defect in latent autoimmune diabetes in adults. Clin Ther (2013) 0.75
A rare case of breast cancer metastasis. Breast Dis (2010) 0.75
Weekly Gemcitabine plus Fluorouracil-Folinic Acid Given Weekly for Two Days in Patients with Advanced Pancreatic Cancer : A Phase II Study. Clin Drug Investig (2004) 0.75
Inflammatory Myopathy and Axonal Neuropathy in a Patient With Melanoma Following Pembrolizumab Treatment. J Immunother (2017) 0.75
Advances and trends in dermato-oncology. Expert Rev Anticancer Ther (2010) 0.75
Encephalitis in a Patient With Melanoma Treated With Immune Checkpoint Inhibitors: Case Presentation and Review of the Literature. J Immunother (2020) 0.75
Late-onset nivolumab-mediated pneumonitis in a patient with melanoma and multiple immune-related adverse events. Melanoma Res (2017) 0.75